Galapagos NV (Euronext & LSE: GLPG) announced today that its service division BioFocus has signed an exclusive marketing & sales agreement with Upstate, a wholly-owned subsidiary of Serologicals Corporation (NASDAQ: SERO), for Galapagos’ adenovirus products worldwide, excluding Japan. Under the terms of the agreement, Upstate, a leader in cell signaling products and services for the drug discovery industry, will put its manufacturing, marketing, sales, customer support and technical assistance organization behind promotion of Galapagos’ adenovirus products. In return, Galapagos will receive double-digit royalties on net sales achieved by Upstate.
